Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364221 | 0.81 | KDR (0.59) | KDREGFR | |
| SCHEMBL4365461 | 0.80 | KDR (0.86) | KDREGFRBRAFLCKPDGFRA | |
| SCHEMBL7847135 | 0.77 | KDR (0.45) | KDREGFRLCKPDGFRAKIT | |
| SCHEMBL4367885 | 0.77 | KDR (0.66) | KDREPHA2EPHB4EGFRBRAF | |
| SCHEMBL5790844 | 0.77 | KDR (0.66) | KDREPHA2EPHB4EGFRBRAF | |
| SCHEMBL6366468 | 0.76 | KDR (0.43) | KDREGFRLCKPDGFRAKIT | |
| SCHEMBL7846902 | 0.76 | KDR (0.45) | KDREGFRRAF1LCKPDGFRA | |
| SCHEMBL7845204 | 0.75 | KDR (0.45) | KDREGFRBRAFRAF1LCK | |
| Hydrochloric Acid SCHEMBL7853846 | 0.70 | RET (0.52) | KDREPHA2EPHB4EGFRLCK | |
| SCHEMBL7850002 | 0.70 | KDR (0.43) | KDREPHB4EGFRBRAFLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885EPHA2 2583/4885EPHB4 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.